Introduction:
A leading pharma stock reported a sharp 54.7% QoQ drop in total income, with revenue falling 65.4%. Net profit declined 80.4%, reflecting weaker sales and higher fixed costs. Despite lower tax expenses, profitability remained under pressure due to declining demand and operational challenges.
Share Price movement of Natco Pharma:
On February 13, 2025, Natco Pharma Limited opened at ₹1,039.10, reaching a high of ₹1,051.25 and a low of ₹992.15, down 17.96% from its previous close of ₹1,218.80. Currently, it is trading at ₹999.95, with a market cap of ₹17,910.09 crore.
Natco Pharma share price rise:
Natco Pharma Ltd reported a steep decline in total income, falling 54.7% QoQ from ₹14,349 crore in Q2 FY25 to ₹6,511 crore in Q3 FY25. Revenue from operations plunged 65.4%, dropping from ₹13,711 crore to ₹4,748 crore, indicating weak sales performance and lower demand.
Total expenses declined 21% QoQ to ₹4,874 crore from ₹6,167 crore, mainly due to lower material costs and stock-in-trade purchases. However, employee benefit expenses slightly decreased by 6.5% to ₹1,416 crore. Operating costs and finance costs remained stable, impacting the company’s overall profitability.
Net profit fell sharply by 80.4% QoQ to ₹1,324 crore from ₹6,765 crore in Q2 FY25. Tax expenses declined significantly from ₹1,541 crore to ₹313 crore, but lower revenue and higher fixed costs weighed heavily on profitability, reflecting weaker financial performance this quarter.
Also Read: Railway stock jumps after it receives order worth ₹537.1 Cr for BCFCM Rakes Wagon
Recent news About Natco Pharma:
On February 10, 2025, Natco Pharma, in partnership with Lupin, announced the approval of their Abbreviated New Drug Application (ANDA) for Bosentan Tablets for Oral Suspension, 32mg, a generic version of Tracleer.
Ace investor holding of Natco Pharma:
Ace investor Akash Bhanshali holds 1.01% stake in Natco Pharma Ltd, owning 1,800,788 shares valued at ₹181.3 crore. His steady investment reflects confidence in the company’s long-term growth potential within the pharmaceutical sector, despite recent stock fluctuations in the market.
Stock performance of Natco Pharma for Period of 1 week, 6 months and 1 year:
Natco Pharma’s stock showed mixed performance across different periods. Over the past week, it declined 8.22%, reflecting short-term volatility. In the last six months, it dropped 16.6%, indicating sustained pressure. However, over the past year, it delivered a 37.8% gain, highlighting long-term strength.
Also Read: Maharatna defence stock jumps after it announces 14.14% YoY growth in net profits
Shareholding pattern of Natco Pharma:
| All values in % | Dec-24 | Sep-24 | Jun-24 |
| Promoters | 49.62 | 49.62 | 49.71 |
| FII | 17.94 | 17.51 | 17.45 |
| DII | 5.59 | 6.76 | 7.86 |
| Retail & others | 26.88 | 26.12 | 24.99 |
About Natco Pharma:
Natco Pharma is a leading Indian pharmaceutical company specializing in niche, complex generics and oncology medicines. With a strong global presence, it focuses on research-driven innovation, API manufacturing, and high-value formulations, catering to both domestic and international markets for sustainable growth.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
